{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T23:25:04Z","timestamp":1771025104330,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s13346-021-01106-1","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:04:35Z","timestamp":1642205075000},"page":"2550-2560","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Synergistic antitumor efficacy of PD-1-conjugated PTX- and ZSQ-loaded nanoliposomes against multidrug-resistant liver cancers"],"prefix":"10.1007","volume":"12","author":[{"given":"Mingjia","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuening","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yali","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinjie","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanjing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiebin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,15]]},"reference":[{"issue":"8","key":"1106_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11604-018-0750-3","volume":"36","author":"Y Shimizu","year":"2018","unstructured":"Shimizu Y, et al. Segmental analysis of respiratory liver motion in patients with and without a history of abdominal surgery. Jpn J Radiol. 2018;36(8):1\u20138.","journal-title":"Jpn J Radiol"},{"issue":"9822","key":"1106_CR2","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","volume":"379","author":"A Forner","year":"2012","unstructured":"Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245\u201355.","journal-title":"Lancet"},{"issue":"15","key":"1106_CR3","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450\u201362.","journal-title":"N Engl J Med"},{"issue":"8","key":"1106_CR4","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.4254\/wjh.v7.i8.1020","volume":"7","author":"A Waghray","year":"2015","unstructured":"Waghray A, Murali AR, Menon KN. Hepatocellular carcinoma: from diagnosis to treatment. World J Hepatol. 2015;7(8):1020.","journal-title":"World J Hepatol."},{"key":"1106_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.phrs.2017.07.023","volume":"126","author":"MS Singh","year":"2017","unstructured":"Singh MS, et al. MDR in cancer: addressing the underlying cellular alterations with the use of nanocarriers. Pharmacol Res. 2017;126:2\u201330.","journal-title":"Pharmacol Res"},{"issue":"16","key":"1106_CR6","first-page":"3620","volume":"58","author":"MS Horwitz","year":"1998","unstructured":"Horwitz MS, Torrespoveda K. Mechanisms of taxol-induced cell death are concentration dependent. Can Res. 1998;58(16):3620\u20136.","journal-title":"Can Res"},{"issue":"12","key":"1106_CR7","first-page":"890","volume":"18","author":"Y-H Yang","year":"2020","unstructured":"Yang Y-H, Mao J-W, Tan X-L. Research progress on the source, production, and anti-cancer mechanisms of paclitaxel. Chin J Nat Med. 2020;18(12):890\u20137.","journal-title":"Chin J Nat Med"},{"key":"1106_CR8","doi-asserted-by":"publisher","first-page":"111059","DOI":"10.1016\/j.biopha.2020.111059","volume":"133","author":"J Jimenez-Lopez","year":"2021","unstructured":"Jimenez-Lopez J, et al. Paclitaxel antitumor effect improvement in lung cancer and prevention of the painful neuropathy using large pegylated cationic liposomes. Biomed Pharmacother. 2021;133:111059.","journal-title":"Biomed Pharmacother"},{"key":"1106_CR9","doi-asserted-by":"publisher","first-page":"9377","DOI":"10.2147\/OTT.S261700","volume":"13","author":"Y Liu","year":"2020","unstructured":"Liu Y, et al. Paclitaxel suppresses hepatocellular carcinoma tumorigenesis through regulating Circ-BIRC6\/miR-877-5p\/YWHAZ axis. Onco Targets Ther. 2020;13:9377\u201388.","journal-title":"Onco Targets Ther"},{"key":"1106_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.actbio.2017.06.017","volume":"58","author":"D Zhu","year":"2017","unstructured":"Zhu D, et al. Folate-targeted polymersomes loaded with both paclitaxel and doxorubicin for the combination chemotherapy of hepatocellular carcinoma. Acta Biomater. 2017;58:399\u2013412.","journal-title":"Acta Biomater"},{"key":"1106_CR11","doi-asserted-by":"publisher","first-page":"102493","DOI":"10.1016\/j.jddst.2021.102493","volume":"63","author":"G Ma","year":"2021","unstructured":"Ma G, et al. Multi-functionalized dendrimers for targeted co-delivery of sorafenib and paclitaxel in liver cancers. J Drug Delivery Sci Technol. 2021;63:102493.","journal-title":"J Drug Delivery Sci Technol"},{"issue":"30","key":"1106_CR12","doi-asserted-by":"publisher","first-page":"35518","DOI":"10.1021\/acsami.1c09610","volume":"13","author":"Z Du","year":"2021","unstructured":"Du Z, et al. TPGS-galactose-modified polydopamine co-delivery nanoparticles of nitric oxide donor and doxorubicin for targeted chemo-photothermal therapy against drug-resistant hepatocellular carcinoma. ACS Appl Mater Interfaces. 2021;13(30):35518\u201332.","journal-title":"ACS Appl Mater Interfaces."},{"key":"1106_CR13","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.biomaterials.2014.10.044","volume":"37","author":"L Cai","year":"2015","unstructured":"Cai L, et al. Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: A synergistic combination nanotherapy for ovarian cancer treatment. Biomaterials. 2015;37:456\u201368.","journal-title":"Biomaterials"},{"issue":"9","key":"1106_CR14","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3109\/1061186X.2015.1020427","volume":"23","author":"M Liu","year":"2015","unstructured":"Liu M, et al. Intracellular target delivery of 10-hydroxycamptothecin with solid lipid nanoparticles against multidrug resistance. J Drug Target. 2015;23(9):800\u20135.","journal-title":"J Drug Target"},{"issue":"3","key":"1106_CR15","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1111\/cbdd.13338","volume":"92","author":"H Ghaleb","year":"2018","unstructured":"Ghaleb H, et al. Design, synthesis and evaluation of a novel series of inhibitors reversing P-glycoprotein-mediated multidrug resistance. Chem Biol Drug Des. 2018;92(3):1708\u201316.","journal-title":"Chem Biol Drug Des"},{"issue":"1","key":"1106_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1080\/10717544.2019.1580797","volume":"26","author":"M Lei","year":"2019","unstructured":"Lei M, et al. Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance. Drug Deliv. 2019;26(1):262\u201372.","journal-title":"Drug Deliv"},{"issue":"6","key":"1106_CR17","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1021\/bc500154c","volume":"25","author":"MM Sprachman","year":"2014","unstructured":"Sprachman MM, et al. In vivo imaging of multidrug resistance using a third generation MDR1 inhibitor. Bioconjug Chem. 2014;25(6):1137.","journal-title":"Bioconjug Chem"},{"key":"1106_CR18","doi-asserted-by":"publisher","first-page":"108852","DOI":"10.1016\/j.biopha.2019.108852","volume":"116","author":"B Baig","year":"2019","unstructured":"Baig B, et al. Current status of nanomaterial-based treatment for hepatocellular carcinoma. Biomed Pharmacother. 2019;116:108852.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"1106_CR19","doi-asserted-by":"publisher","first-page":"1702037","DOI":"10.1002\/smll.201702037","volume":"14","author":"J Lu","year":"2018","unstructured":"Lu J, Wang J, Ling D. Surface engineering of nanoparticles for targeted delivery to hepatocellular carcinoma. Small. 2018;14(5):1702037.","journal-title":"Small"},{"issue":"1","key":"1106_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12645-019-0055-y","volume":"10","author":"E Beltr\u00e1n-Gracia","year":"2019","unstructured":"Beltr\u00e1n-Gracia E, et al. Nanomedicine review: clinical developments in liposomal applications. Cancer Nanotechnol. 2019;10(1):1\u201340.","journal-title":"Cancer Nanotechnol"},{"issue":"2","key":"1106_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101\u201324.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"1106_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40005-016-0260-1","volume":"46","author":"Jin-Seok and Kim","year":"2016","unstructured":"Kim JS. Liposomal drug delivery system. J Pharm Investig. 2016;46(4):387\u201392.","journal-title":"J Pharm Investig"},{"issue":"26","key":"1106_CR23","doi-asserted-by":"publisher","first-page":"8073","DOI":"10.7150\/thno.37198","volume":"9","author":"J Park","year":"2019","unstructured":"Park J, et al. Alliance with EPR effect: combined strategies to improve the EPR effect in the tumor microenvironment. Theranostics. 2019;9(26):8073\u201390.","journal-title":"Theranostics"},{"issue":"1","key":"1106_CR24","doi-asserted-by":"publisher","first-page":"011501","DOI":"10.1063\/5.0029860","volume":"5","author":"MR Aronson","year":"2021","unstructured":"Aronson MR, Medina SH, Mitchell MJ. Peptide functionalized liposomes for receptor targeted cancer therapy. APL Bioeng. 2021;5(1):011501.","journal-title":"APL Bioeng"},{"issue":"11","key":"1106_CR25","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.3390\/jcm9113543","volume":"9","author":"RA de Mello","year":"2020","unstructured":"de Mello RA, et al. New target therapies in advanced non-small cell lung cancer: a review of the literature and future perspectives. J Clin Med. 2020;9(11):3543.","journal-title":"J Clin Med"},{"key":"1106_CR26","doi-asserted-by":"publisher","first-page":"173867","DOI":"10.1016\/j.ejphar.2021.173867","volume":"895","author":"P Setordzi","year":"2021","unstructured":"Setordzi P, et al. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy. Eur J Pharmacol. 2021;895:173867.","journal-title":"Eur J Pharmacol"},{"key":"1106_CR27","doi-asserted-by":"publisher","first-page":"107443","DOI":"10.1016\/j.intimp.2021.107443","volume":"94","author":"L Wu","year":"2021","unstructured":"Wu L, et al. PD-1\/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K\/AKT mediated P-gp expression. Int Immunopharmacol. 2021;94:107443.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1106_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41401-020-0366-x","volume":"42","author":"Q Wu","year":"2021","unstructured":"Wu Q, et al. Small molecule inhibitors targeting the PD-1\/PD-L1 signaling pathway. Acta Pharmacol Sin. 2021;42(1):1\u20139.","journal-title":"Acta Pharmacol Sin"},{"key":"1106_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2147\/OTT.S234868","volume":"13","author":"H Cui","year":"2020","unstructured":"Cui H, Dai G, Guan J. Programmed cell death protein-1 (PD-1)-targeted immunotherapy for advanced hepatocellular carcinoma in real world. Onco Targets Ther. 2020;13:143\u20139.","journal-title":"Onco Targets Ther"},{"issue":"6","key":"1106_CR30","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s12094-018-1975-4","volume":"21","author":"T Mocan","year":"2019","unstructured":"Mocan T, et al. Programmed cell death protein-1 (PD-1)\/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. Clin Transl Oncol. 2019;21(6):702\u201312.","journal-title":"Clin Transl Oncol"},{"key":"1106_CR31","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3389\/fonc.2019.00883","volume":"9","author":"H Liao","year":"2019","unstructured":"Liao H, et al. Expression of programmed cell death-ligands in hepatocellular carcinoma: correlation with immune microenvironment and survival outcomes. Front Oncol. 2019;9:883.","journal-title":"Front Oncol"},{"issue":"1","key":"1106_CR32","doi-asserted-by":"publisher","first-page":"246","DOI":"10.4143\/crt.2016.066","volume":"49","author":"HI Jung","year":"2017","unstructured":"Jung HI, et al. Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res Treat. 2017;49(1):246\u201354.","journal-title":"Cancer Res Treat"},{"issue":"1","key":"1106_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s11671-019-3228-z","volume":"15","author":"J Yu","year":"2020","unstructured":"Yu J, et al. PD-L1 monoclonal antibody-decorated nanoliposomes loaded with paclitaxel and P-gp transport inhibitor for the synergistic chemotherapy against multidrug resistant gastric cancers. Nanoscale Res Lett. 2020;15(1):59.","journal-title":"Nanoscale Res Lett"},{"issue":"1","key":"1106_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1568009033333754","volume":"3","author":"RZ Yusuf","year":"2003","unstructured":"Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003;3(1):1\u20139.","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"1106_CR35","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijpharm.2011.05.082","volume":"416","author":"NR Patel","year":"2011","unstructured":"Patel NR, et al. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm. 2011;416(1):296\u20139.","journal-title":"Int J Pharm"},{"issue":"1","key":"1106_CR36","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1080\/10717544.2020.1797245","volume":"27","author":"D Chen","year":"2020","unstructured":"Chen D, et al. Adjudin-loaded redox-sensitive paclitaxel-prodrug micelles for overcoming multidrug resistance with efficient targeted Colon cancer therapy. Drug Deliv. 2020;27(1):1094\u2013105.","journal-title":"Drug Deliv"},{"key":"1106_CR37","doi-asserted-by":"publisher","first-page":"111523","DOI":"10.1016\/j.colsurfb.2020.111523","volume":"199","author":"MA Farooq","year":"2021","unstructured":"Farooq MA, et al. Enhanced cellular uptake and cytotoxicity of vorinostat through encapsulation in TPGS-modified liposomes. Colloids Surf B Biointerfaces. 2021;199:111523.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1106_CR38","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.2147\/IJN.S290731","volume":"16","author":"Y Hu","year":"2021","unstructured":"Hu Y, et al. Synergistic inhibition of drug-resistant colon cancer growth with PI3K\/mTOR dual inhibitor BEZ235 and nano-emulsioned paclitaxel via reducing multidrug resistance and promoting apoptosis. Int J Nanomedicine. 2021;16:2173\u201386.","journal-title":"Int J Nanomedicine"},{"issue":"9","key":"1106_CR39","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd2614","volume":"7","author":"ME Davis","year":"2008","unstructured":"Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771\u201382.","journal-title":"Nat Rev Drug Discov"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-021-01106-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-021-01106-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-021-01106-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T01:28:41Z","timestamp":1662686921000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-021-01106-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1106"],"URL":"https:\/\/doi.org\/10.1007\/s13346-021-01106-1","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,15]]},"assertion":[{"value":"6 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors whose names appear on the submission approved the version to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}